Here's Why Krystal Biotech, Inc. (KRYS) is a Great Momentum Stock to BuyZacks Investment Research • 11/14/19
Krystal Biotech Announces Granting of its First Foreign Patent and Reinforces its IP Portfolio with a New U.S. PatentGlobeNewsWire • 09/27/19
Krystal Clear: KB-103 Sprints To Become The First Approved Topical Gene Therapy For Skin DiseaseSeeking Alpha • 09/19/19
Krystal Biotech: KB-103 Sprints To Become The First Approved Topical Gene Therapy For Skin DiseaseSeeking Alpha • 09/19/19
Krystal Biotech Announces Initiation of Phase 1/2 Study of KB105 in Transglutaminase-1 (“TGM1”) Deficient Autosomal Recessive Congenital Ichthyosis (“ARCI”)GlobeNewsWire • 09/04/19
Krystal Biotech Announces Attendance at Citi’s 14th Annual Biotech ConferenceGlobeNewsWire • 08/27/19
Krystal Biotech Analyst Lifts Price Target More Than 50% On Positive Phase 2 Data, RMAT DesignationBenzinga • 06/25/19
Krystal Biotech shares up 27% after company's skin drug receives expedited review designation from FDAMarket Watch • 06/24/19
